Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs

Cell Cycle

Volumn 9, Issue 8, 2010, Pages 1629-1638

  Steelman, Linda S ^a   Abrams, Stephen L ^a   Shelton, John G ^a   Chappell, William H ^a   Bäsecke, Jörg ^b   Stivala, Franca ^c   Donia, Marco ^c   Nicoletti, Ferdinando ^c   Libra, Massimo ^c   Martelli, Alberto M ^d,e   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CNR   (Italy)

Author keywords

Akt; Cell cycle progression; Chemotherapeutic drugs; Drug resistance; Raf; Signal transduction inhibitors

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PACLITAXEL; PROTEIN AKT 1; PROTEIN KINASE B; RAF PROTEIN; RAF1 PROTEIN; RAPAMYCIN; S6 KINASE; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL LINE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE ACTIVATION; GENE EXPRESSION; GENE INDUCTION; ONCOGENE; TIME;

EID: 77953598922     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.8.11487     Document Type: Article

References (52)

1. Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Basecke J, et al. Contributions of the Raf/ MEK/ERK, PI3K/PTEN/Akt/mTOR and JAK/STAT pathways to leukemia. Leukemia 2008; 22:686-707.
2. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, et al. Targeting Survival cascades induced by activation of Raf/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22:708-22.
3. Carracedo A, Baselaga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008; 7:3805-9.
4. Misaghian N, Ligresti G, Steelman LS, Bertand FE, Basecke J, Libra M, et al. Targeting the leukemic stem cell - the holy grail of leukemia therapy. Leukemia 2009; 23:25-42.
5. McKearn JP, McCubrey JA, Fagg B. Enrichment of hematopoietic precursor cells and cloning of multipotential B lymphocyte precursors. Proc Natl Acad Sci USA 1985; 85:7414-8. (Pubitemid 16196830)
6. McCubrey JA, Holland G, McKearn J, Risser R. Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms. Oncogene Res 1989; 4:97-109. (Pubitemid 19121771)
7. Mayo MW, Wang X-Y, Algate PA, Arana GF, Hoyle PE, Steelman LS, et al. Synergy between AUUUA motif disruption and enhancer insertion results in autocrine transformation of interleukin-3-dependent hematopoietic cells. Blood 1995; 78:3139-50.
8. Wang X-Y, McCubrey JA. Malignant transformation induced by cytokine genes: A comparison of the abilities of germline and mutated interleukin-3 genes to transform hematopoietic cells by transcriptional and post-transcriptional mechanisms. Cell Growth Differ 1996; 7:487-500.
9. Wang XY, McCubrey JA. Differential effects of retroviral long terminal repeats on interleukin-3 gene expression and autocrine transformation. Leukemia 1997; 11:1711-25.
10. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong ET, Basecke J, et al. Involvement of p53 and Raf/ MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008; 22:2080-90.
11. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108:2358-65.
12. Gomes AR, Brosens JJ, Lam EWF. Resist of die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008; 7:3133-6.
13. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009; 8:1352-8.
14. 2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage. Cell Cycle 2008; 7:2877-85.
15. Hambardumyan D, Becher OJ, Holland EC. Cancer stem cells and survival pathways. Cell Cycle 2008; 7:1371-8.
16. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT in NOTCH1-induced leukemia. Cell Cycle 2008; 7:965-70.
17. Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, et al. Proapoptotitc activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22:147-60.
18. Lee JT, Lehmann BD, Terrrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7:1745-62.
19. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007; 21:886-96.
20. Fernandez-Vidal A, Mazars A, Gautier ER, Prevost G, Payrastre B, Manenti S. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. Cell Cycle 2009; 8:1373-9.
21. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21:427-38. (Pubitemid 46306553)
22. Follo MY, Finelli C, Bosi C, Martinelli G, Mongiorgi S, Baccarani M, et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008; 22:198-200.
23. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, et al. The novel Akt inhibitor perifosine induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22:1106-16. (Pubitemid 351833776)
24. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, et al. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 2003; 22:2478-92.
25. Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 2001; 20:4353-64.
26. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/ Akt/mTOR pathway inhibitors in suppressing IGFIR-mediated growth in hematopoietic cells. Leukemia 2006; 20:1254-60.
27. Steelman LS, Navolanic PN, Sokolosky M, Taylor JR, Lehmann BD, Chappell WH, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity of mTOR inhibitors. Oncogene 2008; 27:4086-95. (Pubitemid 351931994)
28. Tallman MS. New agents for the treatment of acute myeloid leukemia. (Review) Baillieres Best Pract Res Clin Haematol 2006; 19:311-20.
29. Poruchynsky MS, Sackett DL, Robey RY, Ward Y, Annunziata C, Fojo T. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008; 7:1940-9. (Pubitemid 351573790)
30. Mathew G, Timm ER Jr, Sotomayor P, Godoy A, Montecinous VP, Smith GJ, et al. ABCG2-mediated dye cycle violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009; 8:1053-61.
31. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009; 8:403-13.
32. Mavrakis KJ, Wendel HG. Translational control and cancer therapy. Cell Cycle 2008; 7:2791-4.
33. Dal Col J, Dolcetti R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle 2008; 7:2813-6.
34. Feng Z, Hu W, Rajagopal G, Levine AJ. The tumor suppressor p53: cancer and aging. Cell Cycle 2008; 7:842-7. (Pubitemid 351573774)
35. Kortchina LG, Demidenko ZN, Gudkov AV, Blagosklonny MV. Cellular quiescence caused by the Mdm-2 inhibitor nuttlin 3A. Cell Cycle 2009; 15:3777-81.
36. Pospelova TV, Demidenko ZN, Bukreeva EI, Poselov VA, Gudkov AV, Blagosklonny MV. Pseudo DNA damage response in senescent cells. Cell Cycle 2009; 8:4112-8.
37. Silva RL, Wendel HG. MNK, EIF4E and targeting translation for therapy. Cell Cycle 2008; 7:553-5.
38. Chiarini F, Fala F, Tazzari PL, Ricci F, Astolfi A, Pession A, et al. Dual inhibition of class IA phosphatidylionsitol 3-kinase and mTOR as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009; 69:3520-8.
39. Sklandanosdki A, Bozko P, Sabisz M, Larsen AK. Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle 2007; 6:2268-75. (Pubitemid 47547705)
40. Foster DA, Toschi A. Targeting mTOR with rapamycin: one does not fit all. Cell Cycle 2009; 8:1026-9.
41. Blagosklonny MV. Aging: ROS or TOR. Cell Cycle 2008; 7:3344-54.
42. Blagosklonny MV, Campisi J. Cancer and aging: more puzzles, more promises. Cell Cycle 2008; 7:2615-8.
43. Blagosklonny MV. Program-like aging and mitochondria: instead of random damage by free radicals. J Cell Biochem 2007; 102:1389-99.
44. Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896-900.
45. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle 2009; 8:1901-4.
46. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008; 7:3355-61.
47. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888-95.
48. Blagosklonny MV. Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic decleration. Cell Cycle 2009; 8:1883-7.
49. Blagosklonny MV. Aging, stem cells and mammalian target of rapamycin: a prospect of pharmalogical rejuvenation of aging stem cells. Rejuvenation Res 2008; 11:801-8.
50. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007; 6:1684-90.
51. Stuart SA, Minami Y, Wang JYJ. The CML stem cell: evolution of the progenitor. Cell Cycle 2009; 8:1338-43.
52. Li L, Borodyansky L, Yang Y. Genomic instability en route to and from cancer stem cells. Cell Cycle 2009; 8:1000-2.